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Background: It was our purpose to analyze long-term clinical outcome and to identify prognostic factors after
Linac-based fractionated stereotactic radiotherapy (Linac-based FSRT) and stereotactic radiosurgery (SRS) in patients
with intracranial meningiomas.
Materials and methods: Between 10/1995 and 03/2009, 297 patients with a median age of 59 years were treated
with FSRT for intracranial meningioma. 50 patients had a Grade I meningioma, 20 patients had a Grade II meningioma,
12 patients suffered from a Grade III tumor, and in 215 cases no histology was obtained (Grade 0). Of the 297 patients,
144 underwent FSRT as their primary treatment and 158 underwent postoperative FSRT. 179 patients received
normofractionated radiotherapy (nFSRT), 92 patients received hypofractionated FSRT (hFSRT) and 26 patients
underwent SRS. Patients with nFSRT received a mean total dose of 57.31 ± 5.82 Gy, patients with hFSRT received a
mean total dose of 37.6 ± 4.4 Gy and patients who underwent SRS received a mean total dose of 17.31 ± 2.58 Gy.
Results: Median follow-up was 35 months. Overall progression free survival (PFS) was 92.3% at 3 years, 87% at 5 years
and 84.1% at 10 years. Patients with adjuvant radiotherapy showed significantly better PFS-rates than patients who had
been treated with primary radiotherapy. There was no significant difference between PFS-rates of nFSRT, hFSRT and
SRS patients. PFS-rates were independent of tumor size. Patients who had received nFSRT showed less acute toxicity
than those who had received hFSRT. In the Grade 0/I group the rate of radiologic focal reactions was significantly lower
than in the atypical/malignant histology group.
Conclusion: This large study showed that FSRT is an effective and safe treatment modality with high PFS-rates for intra-
cranial meningioma. We identified “pathological grading” and and “prior surgery” as significant prognostic factors.
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Meningioma is the second most common primary intra-
cranial tumor that arises from the cap cells of the arach-
noid membrane and is more common in women than in
men, incidence peaks in the fifth, sixth, and seventh dec-
ade [1]. About 85% of meningiomas are slow growing
Grade I tumors, approximately 10% are Grade II atypical
lesions, and 3–5% are anaplastic Grade III lesions.
Microsurgical resection is usually the treatment of
choice for symptomatic tumors but may not always be
possible, due to proximity to critical structures. Higher
Grade tumors have higher risks of recurrence after* Correspondence: David.Kaul@charite.de
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unless otherwise stated.surgical resection [2,3]. Postoperative FSRT may prolong
time to recurrence and is usually recommended after in-
complete resection. Inoperable symptomatic Grade I
meningiomas can be treated using FSRT with results
comparable to those of complete resection [4,5].
Grade II meningiomas are found in 5-20% of the pa-
tients; 40-60% of these patients remain disease-free at
10 years after definitive treatment [6,7]. Grade III tumors
account for 1-5% and recurrence-free survival is usually
less than 2 years [7]. Grade II/III meningiomas are com-
monly treated with postoperative FSRT after incomplete
or complete resection [8,9]. In the present study, we an-
alyzed the results in one of the largest populations of
meningioma-patients treated with Linac-based image-
guided FSRT in a single institution. The purpose was to
gain information on long-term clinical outcome, relevant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Methods
Treatment decisions, patient selection and dose regimens
We performed a retrospective analysis of 372 patients
who underwent FSRT of an intracranial meningioma
between 10/1995 and 03/2009. 5 patients receiving re-
irradiation due to a secondary meningioma were ex-
cluded. In 3 patients the diagnosis was questionable, 62
patients were excluded because of incomplete follow-
up. In 5 patients the fractionation scheme was not de-
terminable. Follow-up data were analyzed until March
2010. The study was approved by the local Ethics
Committée of Charité University Medicine, Berlin.
The research was in compliance with the Helsinki
Declaration.
In our institution treatment decisions are based on an
interdisciplinary vote. Adjuvant FSRT is offered to all
resected Grade II and III meningioma-patients; Symp-
tomatic Grade I meningiomas are treated with adjuvant
RT only after incomplete resection or when recurrence
occurs after total resection. Inoperable Grade II or III
tumors as well as inoperable symptomatic Grade I tu-
mors are treated using primary FSRT.
1.6-2.2 Gy were considered normofractionated (nFSRT),
2.2-5 Gy were considered hypofractionated (hFSRT) and
high single doses delivered in less than 5 sessions were
considered stereotactic radiosurgery (SRS).
Tumors in close proximity to critical structures were
assigned to nFSRT, while large tumors (> 2 cm) distant
to critical structures underwent hFSRT and small tumors
(< 2 cm) were treated by SRS.
Stratification and variables
Patient data were analyzed according to grading, loca-
tion, predicted peri-operative risk/operability, tumor size
and sequence of therapy. Two groups were defined:
group 1 encompasses all Grade I meningiomas, as well
as all meningiomas with no histology available (Grade 0).
Group 2 encompasses all Grade II and III meningiomas.
The tumor location was divided into 3 groups accord-
ing to the Novel “CLASS” Algorithmic Scale for Patient
Selection in Meningioma Surgery: low risk, medium risk,
high risk and optical nerve sheath (ONSM) [10].
Follow-up examinations, including MRI as well as clin-
ical, and neurologic examinations were performed at
6 weeks, 3 months, 9 months, 15 months after treatment
and then annually.
We distinguished between primary radiation treatment
and postoperative radiotherapy. Acute toxicity in the
first 90 days after FSRT was graded using a modified
version of the Common Terminology Criteria of Adverse
Events (CTCAE v4.0).Technical set-up
From 1995–2003 meningioma patients underwent “sharp”
fixation using a stereotactic head ring and an oral bite
Plate. A 6 MV Linac (Varian® USA) with an add-on
micro-multileaf collimator (mMLC) (BrainLab® Co,
Germany) was used. Coordinats for SRS were set by a
laser-based stereotactic localizer. This set up allowed de-
livering shaped beams. In 2004 we started using Novalis®
(BrainLab®) with beam shaping capability using build-in
MLC and image guidance. Novalis ExacTrac® image
guided frameless system enabled us to image the patient
at any couch position using a frameless positioning array.
MRI/CT-fusion planning was performed. The three-
dimensional treatment planning system Brainscan® (Brain
Lab AG, Germany) was used, which was later replaced by
iplanRT®. The gross tumor volume (GTV) was defined as
the area of contrast enhancement on T1-weighted MRI
images, the planning target volume (PTV) included a
2 mm isotropic safety margin. The dose was prescribed to
a reference point, which was the isocenter (or the center
of GTV), though 100% was not the maximum dose but
the dose at the aforementioned reference point. Patients re-
ceived the prescribed dose to the 80th isodose at the tumor
margin plus a safety margin of 5 mm in Grade II and III
meningiomas. Organs at risk (OAR) such as optic nerves,
the chiasm, lenses and the brainstem, were delineated.
Dose constraints were according to the data published by
Emami et al. 1991 [11]. The TD 5/5 to be respected was as
follows: for optic nerves 50 Gy, for chiasm 50 Gy, for lenses
10 Gy and for the brainstem 50 Gy, respectively.
Formulas and statistics
The equivalent 2 Gy dose (EQD2) was calculated accord-
ing to the formula, EQD2 = n × d × (a/b + d)/(a/b + 2).
All statistical analyses were performed using IBM SPSS
Statistics 19 (New York, USA).
Results
Patients
297 meningioma patients treated in our department be-
tween October 1995 and March 2009 were included in the
analysis. Patient characteristics are summarized in Table 1.
Localization
Tumors were grouped according to the “CLASS” Algo-
rithmic Scale for Patient Selection in Meningioma Sur-
gery: 9.8% had a low risk localization, 13.5% showed a
moderate risk localization, 71.7 showed s high risk
localization and 5.1 percent were ONSM.
Progression free survival
PFS-rates are summarized in Table 2. In the entire co-
hort progression free survival was 92.3% after 3 years,
87% after 5 years and 84.1% after 10 years (Figure 1).
Table 1 Characteristics of the 297 meningioma patients analyzed
Overall collective Group 1 Group 2
(n = 297) U/WHO1 WHO2/3
(n = 265) (n = 32)
Mean Min/Max Mean Min/Max Mean Min/Max
Age with beginn of RT 59 20/87 59 20/87 60.13 38/76
Mean volume 15.01 0.26/190.85 15.77 0.26/190.85 6.62 0.84/27.42
n % n % n %
Gender m 95 32 75 28.3 20 62.5
f 202 68 190 71.7 12 37.5
Location Skull Base 254 85.5 246 92.8 8 25
Falx/Parasagittal 20 6.7 10 3.8 10 31.3
Convexity 23 7.7 9 3.4 14 43.8
WHO grading n/a 215 72.4 215 81.2 - -
WHO 1 50 16.8 50 18.9 - -
WHO 2 20 6.7 - - 20 62.5
WHO 3 12 4.0 - - 12 37.5
Prior surgery Primary RT 144 48.5 143 54 1 3.1
Adjuvant RT 153 51.5 122 46 31 96.9
Peritumoral edema yes 13§ 6.6 12Ÿ 6.7 1 5.56$
Multiple meningiomas yes 58 19.5 52 19.6 6 18.8
Fractionation Scheme FSRT 179 60.3 158 59.6 21 65.6
hFSRT 92 31.0 82 30.9 10 31.3
SRS 26 8.8 25 9.4 1 3.1
Mean total dose 47.7 13.5/95.4 47.1 13.5/63 52.4 15/95.4






3 years 5 years 10 years
Entire cohort 92.30% 87.00% 84.10%
Group 1 (unknown/Grade I) 96.80% 92.70% 89.60%
Group 2 (Grade II/III) 52.60% 19.70% n/a
Unknown histology 97.40% 94.20% 90.40%
Grade I 93.90% 85.80% 85.80%
Grade II 62.70% 41.80% n/a
Grade II 29.30% n/a n/a
Volume < 60 ccm 95.80% 91.20% 89.30%
Volume > 60 ccm 100% 85.70% n/a
Primary RT 98.10% 98.10% 96.80%
Postoperative RT 87.60% 78.10% 73.40%
nFSRT 92.70% 88.90% 86.90%
hFSRT 92.40% 80.90% n/a
SRS 95.80% 87.80% n/a
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96.8%, 92.7% and 89.6% at 3, 5 and 10 years (Figure 2). Pa-
tients with histologically proven Grade I meningioma
showed PFS-rates of 93.9% after 3 years and 85.8% after
5 years and 10 years and patients with unknown histology
showed PFS-rates of 97.4%, 94.2% and 90.4% for 3, 5 and
10 years (Figure 3), there was no significant difference be-
tween PFS-rates of proven Grade I tumors and tumors of
unknown histology (p = 0.172, Log-Rank Test). In the
Grade II/III group PFS-rates were 52.6% after 3 years and
19.7% after 5 years, 10 year rates could not be calculated
since all cases had been censored (Figure 2). The differ-
ence in PFS-rates between group 1 and group 2 was highly
significant in the Log-Rank Test (p < 0.0001). Patients with
Grade II meningioma had PFS-rates of 62.7% after 3 years
and 41.8% after 5 years, 10 year rates could not be calcu-
lated since all cases had been censored (Figure 3).
Patients with a target volume of more than 60 cm3
have been described to have significantly worse local
control rates [12]. In this study tumors with a volume
below 60 cm3 had no significantly better PFS-rate than
Figure 1 PFS-rates of the entire cohort.
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though, that there is a bias in treatment selection, since
tumors with a diameter < 2 cm usually received SRS.
An analysis of the factor “prior surgery” showed sig-
nificant differences in PFS-rates. Patients who hadFigure 2 PFS-rates of group 1 and group 2. There is a significant differeundergone surgical resection showed worse PFS-rates
(Figure 5).
Patients with nFSRT received a mean total dose of
57.31 ± 5.82 Gy, patients with hFSRT received a mean
total dose of 37.6 ± 4.4 Gy and patients who underwentnce between the PFS-rates of both groups (p < 0.001; Log-Rank Test).
Figure 3 PFS-rates for meningiomas of unknown histology as well as GradeI I, II and III meningiomas. There is no significant difference
between the PFS-rates of meningiomas of unknown histology and Grade I tumors (p = 0.172; Log-Rank Test). Unknown histology vs. Grade II (p <
0.0001; Log-Rank Test), unknown histology vs. Grade III (p < 0.0001; Log-Rank Test), Grade I vs. Grade II (p < 0.002; Log-Rank Test), Grade I vs. Grade III
(p < 0.0001; Log-Rank Test).
Figure 4 PFS-rates of patients with tumors above and below 60 cm3. There is no significant difference between the PFS-rates of patients
with tumors above and patients with tumors below 60 cm3 (p = 0.768; Log-Rank Test).
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Figure 5 PFS-rates for patients with primary and postoperative FSRT. There was a significant difference in PFS-rates for patients treated with
primary and adjuvant FSRT (p < 0.001 Log-Rank Test).
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values translate into EQD210-values of 56.37 ± 5.72 Gy for
nFSRT, 45.17 ± 3.26 Gy for hFSRT and 38.93 ± 9.66 Gy for
SRS. There was no significant difference in terms of PFS-
rates between nFSRT, hFSRT and SRS treatment. the 3
groups (p = 0,811; Log-Rank Test) (Figure 6).Radiologic response
Radiologic response was evaluated using MRI (T1, T2
and FLAIR sequence). Response rates are shown in
Table 3. In group 1 252 patients (95.1%) were locally
controlled, 18.1% tumor regression. Only 4.9% of pa-
tients showed local progression. In the atypical/malig-
nant histology group worse local control was seen
(62.5%, p < 0.001), but interestingly there was no signifi-
cant difference between group1 and group 2 when look-
ing at tumor regression (18.1% in group 1 vs. 15.6% in
group 2). In our analysis of subgroups none of the fol-
lowing variables showed significant influence on tumor
regression, neither “tumor volume” nor “prior surgery”
nor the fractionation scheme.Acute toxicity
The most common acute Grade I symptoms for the en-
tire cohort were headache, fatigue, local alopecia andlocal skin reaction. The most common acute Grade II
symptoms were headache, vertigo and nausea.
The difference in acute toxicity between group 1 and
group 2 was not significant.
Patients with tumors smaller than 60 cm3 did not
show a significantly different rate of acute toxicity than
patients with a tumor diameter above 60 cm3 (n = 192,
p = 0.28). As mentioned above though there is a bias in
treatment, since smaller tumor usually received SRS.
There was a significant difference in acute toxicity for
different fraction schemes: Patients receiving nFSRT
showed more acute toxicity compared to hFSRT or SRS
(67.1% vs. 47.9% and 35%). This difference was mainly
due to Grade I reactions (FSRT: 50.3%, hFSRT: 31% SRS:
10%; p < 0.001), Grade II and III reactions were even a
bit higher in Patients receiving hFSRT or SRS, although
this effect was not significant.Late toxicity
For n = 276 patients (92.9%) of the entire cohort evalu-
ation of late toxicity was available, 98 (35.5%) showed
late toxicity. The most common Grade I symptoms were
headache and fatigue. The most common Grade II
symptoms were headache, dizziness and seizures. Grade
III late toxicity was seen 0.7% of the patients.
Figure 6 PFS-rates for patients with normofractionated, hypofractionated and radiosurgical treatment. There was no significant
difference between the 3 groups (p = 0.811; Log-Rank Test).
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group 2 was not significant.
Focal reactions and corticosteroid treatment
New peritumoral edema during follow-up was described
in 14.8% of all patients in the entire cohort. In group 1
the rate of focal reaction was significantly lower than in
group 2; 12.8% compared to 31.2% (p = 0.014).
Therapy with corticosteroids was necessary in 12.8%
of the patients. There was no significant difference be-
tween group 1 and group 2 concerning treatment with




Group 1 n 13 204 48 265
% 4.9% 77% 18.1% 100.0%
Group 2 n 12 15 5 32
% 37.5% 46.9% 15.6% 100.0%
Overall collective n 25 219 53 297
% 8.4% 73.7% 17.8% 100.0%Discussion
This study is the second largest analysis of Linac-based
FSRT for intracranial Grade I-III meningiomas after the
study by Milker-Zabel et al. [13]. We show here that
Linac-based FSRT is a safe option in the treatment of
intracranial meningiomas with a low risk of acute or late
toxicity and can thus corroborate the findings by
Milker-Zabel et al. Patients with meningiomas that score
high on the “CLASS” -scale are more likely to receive
primary radiotherapy meaning that the patients have
undergone negative preselection. Considering this fact
the good PFS rates seen after radiotherapy are even
more encouraging.
In the entire cohort (Grade 0-III) progression free sur-
vival was 92.3% at 3 years, 87% at 5 years and 84.1% at
10 years. Similar results have been shown for gamma
knife radiosurgery of Grade I-III meningiomas by
Nakaya et al. who found PFS-rates of 94%, 83%, and 58%
at 3, 5 and 10 years respectively [14].
In the benign/unknown histology group PFS-rates
were 96.8%, 92.7% and 89.6% at 3, 5 and 10 years. In a
study by Compten et al. similar PFS-rates for FSRT-
treated benign and unknown histology meningiomas are
shown: 96.3% at 3 years and 93% at 5 years [15].
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Grade I meningioma PFS-rates were 93.9% at 3 years
and 85.8% at 5 years and at 10 years. Milker-Zabel et al.
found similar PFS-rates of 98.5% at 3 years, 90.5% at
5 years, and 89% at 10 years for FSRT-treated Grade I
meningiomas. In a study by Debus et al. the overall actu-
arial survival rate of patients with WHO Grade I men-
ingioma was 97% at 5 years and 96% at 10 years [16].
Kreil et al. showed similar results for benign histology
meningiomas treated with gamma knife radiosurgery:
98.5% at 5 years and 97.2% at 10 years [17].
We found that group 2 had PFS-rates 52.6% at 3 years
and 19.7% at 5 years, 10 year rates could not be calcu-
lated since all cases had been censored. Compten et al.
showed a slightly lower PFS-rate of 40% for GradeII/III
meningiomas at 3 years [15].
Patients with Grade II meningioma had PFS-rates of
62.7% at 3 years and 41.8% at 5 years, 10 year rates
could not be calculated since all cases had been cen-
sored. Milker-Zabel et al. showed better recurrence-free
survival rates of 96% at 3 years, 89% at 5 years, and 67%
at 10 years for Grade II meningiomas [12]. However
these data might might be a statistically biased due to
the small number of patients with proven Grade II
meningioma.
In general it must be mentioned that the role of adju-
vant radiotherapy of Grade II/III meningiomas remains
unclear due to inconsistent evidence from retrospective
studies [18].
Independent of histology we showed 5 year PFS-rates
of 96.8% for patients who had undergone primary radi-
ation and 78.1% for patients who had received surgical
resection. Nutting et al. found a 5-year PFS-rate of 92%
in patients with benign meningiomas which had been
treated with adjuvant conventional FSRT after surgery
[19]. In a study by Goldsmith et al. a 5-year progression-
free survival rate of 89% was reported for patients with
subtotally resected Grade I meningioma after postopera-
tive FSRT [20].
We found a significant difference in PFS-rates for pa-
tients who had undergone surgical resection and those
who had received primary radiation (p < 0.001, log-rank
test). This result was to be expected since Grade I men-
ingiomas are usually not treated with adjuvant FSRT
after complete resection.
Milker-Zabel et al. found that patients with a tumor vol-
ume >60 cm3 had a higher recurrence rate than patients
with a lower tumor volume. We did not find significant
differences in PFS-rates between these two groups. How-
ever, considering that only 11 of the entire cohort showed
a tumor volume above 60 cm3, the number of cases ana-
lyzed here might just be to low to be significant.
We found that patients with nFSRT showed more
acute toxicity than those with hFSRT or SRS. Thisdifference was mainly due to Grade I reactions. The rate
of Grade II and III reactions was higher in patients who
received hFSRT or SRS (however this effect was not sig-
nificant). This might be due to the prolonged treatment
in nFSRT-patients. These patients had the time to develop
Grade I reactions whereas hypofractionated patients might
have skipped Grade I reactions and developed Grade II/III
reactions faster.
In the entire cohort 35.5% of the patients showed late
toxicity. Compten et al. found late toxicity in 20.8% of
meningioma patients after FSRT. Hamm et al. found late
toxicity of only 14.3% in a cohort of 224 patients (183
nFSRT, 30 hFSRT and 11 SRS). However it has to be no-
ticed that retrospective analyses of toxicity are bias-prone
due to interobserver variabilities. Also the relatively high
total dose delivered may play a role here.
Engenhart et al. who found 30% of patients to show
chronic late toxicity after a mean single fraction dose of
29 Gy which is similar to 36% late toxicity found in SRS
patients in this study [21].
We found Grade III late toxicity in 0.7% of the pa-
tients, which is similar to the results shown in a study
by Goldsmith et al. where 3.6% of 140 patients treated
with a radiation dose of 57.6 Gy showed Grade III late
toxicity [20]. Jalali et al. found chronic late toxicity in 6%
of 67 patients [22].
In our study new peritumoral edema was described in
14.8% of all patients in the entire cohort, slightly worse
results were found in a study by Chang et al., where
radiologic complications were seen in 23.6% of 179 pa-
tients treated with gamma knife radiosurgery after a
mean follow-up of 37.3 months [23].Conclusion
The good long-term clinical outcome of FSRT in regard
to its high effectiveness and low morbidity is indicating
that it should be considered as an equivalent treatment
option complementary to microsurgery and gamma
knife radiosurgery.
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